References
- Hulley SB, Rosenman RH, Bawol RD, et al. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N EnglJ Med 1980: 302(25): 1383–9
- Austin MA. Plasma triglyceride as a risk factor for coronary heart disease: the epidemiologic evidence and beyond. Am J Epidemiol 1989: 129(2): 249–59
- Stender S, Zilversmit DB. Transfer of plasma lipoprotein components and of plasma proteins into aortas of cholesterol-fed rabbits: molecular size as a determinant of plasma lipoprotein influx. Arteriosclerosis 1981: 1(1): 38–49
- Innerarity TL, Arnold KS, Weisgraber KH, et al. Apolipoprotein E is the determinant that mediates die receptor uptake of beta-very low density lipoproteins by mouse macrophages. Arteriosclerosis 1986: 6(1): 114–22
- Brunzell JD, Sniderman AD, Albers JJ, et al. Apoproteins B and A-I and coronary artery disease in humans. Arteriosclerosis 1984: 4(2): 79–83
- Sniderman AD, Silberberg J. Is it time to measure apolipoprotein B? Arteriosclerosis 1990: 10(5): 665–7
- Vega GL, Grundy SM. Does measurement of apolipoprotein B have a place in cholesterol management? Arteriosclerosis 1990: 10(5): 668–71
- Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975: 1 (7897): 16–9
- Assman G, Funke H. HDL metabolism and atherosclerosis. J Cardiovasc Pharmacol 1990: 16(Suppl 9): S15–20
- Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation 1983: 67(4): 730–4
- Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988: 148(1): 36–69
- Wilson DE, Lees RS. Metabolic relationships among the plasma lipoproteins: reciprocal changes in the concentrations of very low and low density lipoproteins in man. J Clin Invest 1972: 51(5): 1051–7
- Vega GL, Grundy SM. Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations: comparison of gemfibrozil vs lovastatin therapy. JAMA 1990: 264(21): 2759–63
- Huttunen JK, Manninen V, Mänttäri M, et al. The Helsinki Heart Study: central findings and clinical implications. Ann Med 1991: 23: 155–9
- East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med 1988: 109(1): 25–32
- Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990: 264(1): 71–5
- Carlson LA, Wahlberg G. Relative increase in apolipoprotein CII content of VLDL and chylomicrons in a case with massive type V hyperlipoproteinaemia by nicotinic acid treatment. Atherosclerosis 1978: 31(1): 77–84
- Leaf DA, Connor WE, Illingworth DR, et al. The hypolipidemic effects of gemfibrozil in type V hyperhpidemia: a double-blind, crossover study. JAMA 1989: 262(22): 3154–60